Market capitalization | $854.98m |
Enterprise Value | $647.89m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.19 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-260.43m |
Free Cash Flow (TTM) Free Cash Flow | $-192.10m |
Cash position | $335.52m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
11 Analysts have issued a Cogent Biosciences Inc forecast:
11 Analysts have issued a Cogent Biosciences Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -4.04 -4.04 |
8%
8%
|
|
EBITDA | -256 -256 |
35%
35%
|
EBIT (Operating Income) EBIT | -260 -260 |
34%
34%
|
Net Profit | -242 -242 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Andrew Robbins |
Employees | 164 |
Founded | 2014 |
Website | www.cogentbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.